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Abstract
Background: In mammalian cells regulatory proteins controlling the cell cycle are necessary due to the requirements of
living in a heterogeneous environment of cell-interactions and growth factors. VRK1 is a novel serine-threonine kinase that
phosphorylates several transcription factors and is associated with proliferation phenotypes.
Methodology/Principal Findings: In this report VRK1 has been identified as regulated in the cell cycle. VRK1 gene
expression is activated by the addition of serum to starved cells, indicating it is required for the exit of G0 phase and entry in
G1; a response that parallels the re-expression of MYC, FOS and CCND1 (cyclin D1) genes, suggesting that VRK1 is an early-
response gene. VRK1 gene expression is also shutdown by serum withdrawal. The human VRK1 gene promoter cloned in a
luciferase reporter responds similarly to serum. In response to serum, the level of VRK1 protein expression has a positive
correlation with cell proliferation markers such as phosphorylated-Rb or PCNA, and is inversely correlated with cell cycle
inhibitors such as p27. The elimination of VRK1 by siRNA results in a G1 block in cell division, and in loss of phosphorylated-
Rb, cyclin D1, and other proliferation markers. Elimination of VRK1 by siRNA induces a reduction of cell proliferation. VRK1
colocalizes with p63 in proliferating areas of squamous epithelium, and identifies a subpopulation in the basal layer.
Conclusions/Significance: VRK1 is an immediate early response gene required for entry in G1, and due to its implication in
normal cell proliferation and division, might be a new target for development of inhibitors of cellular proliferation.
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Introduction
The cell cycle is a tightly regulated process required to
guarantee the correct transmission of genetic information to
daughter cells. The basic mechanism governing progression
through the cycle is mediated by CDK/cyclins [1–4], a basic
mechanism conserved from lower to higher eukaryotes that also
has additional sophisticated control checkpoints in mammalian
cells [5–8]; although some CDK appear to be dispensable [9].
However the cycle occurs in many different cell types ranging from
stem cells, transit amplifying cells or tumor cells; and also in the
context of an extracellular environment that is conditioned by
homo and heterotypic cell interactions as well as variable
characteristics of the extracellular matrix [10–12]. These different
environmental conditions suggest that additional pathways and
proteins must impinge on cell cycle progression or regulation that
may be dependent on either cell type or growth conditions.
Recently a new family of serine-threonine kinases has been
identified in the human kinome. This family known as the vaccinia-
related kinases is composed of three members. VRK1 is the most
characterized member [13] and it phosphorylates several proteins
suchas p53 [14], c-Jun [15],ATF2[16] among transcription factors,
or Baf, a protein required for nuclear envelope assembly [17,18].
VRK1 specifically phosphorylates p53 in Thr18 resulting in its
stabilization and transcriptional activation [14,19]; and the resulting
accumulation of p53 induces a proteolytic downregulation of VRK1
protein levels forming a novel autoregulatory loop [20] that is
disruptedinlungsquamouscellcarcinomaswithp53mutations[21].
It has been postulated that VRK1 plays a role in maintaining a p53
molecule in a readiness state so that it can respond to any minor
damage before DNA replication occurs [19], this suggests that
VRK1 must be necessary relatively early in the G1 phase of the cell
cycle, probably before the restriction point. Several additional lines
of evidence suggest that VRK1 might be playing a role in relation
with cell cycle progression. In normal human squamous epithelium,
VRK1 protein presents a pattern of expression that overlaps that of
the Ki67 proliferation marker, and coincides with the transit
amplification compartment [22]. A similar correlation with this
marker has been also detected in human head and neck squamous
cell carcinomas, where it was correlated with other markers related
with the proliferation phenotype, such as CDK2, CDK6, cyclin A
and B1, topoisomerase II and survivin [22]. The use of siRNA
specific for VRK1 caused a defective cell division in a colon tumor
cellline[19].Furthermore, inC.elegans the inactivation of the unique
Vrk-1 ortholog gene was embryonic lethal, and in adult worms
presented a slow growth phenotype [23]. In murine hematopoietic
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timeof massive cellular expansionindays E11.5 toE13.5[24],and a
similar finding was observed in murine developing retina [25]. All
these data are consistent with a role for human VRK1 in cell cycle.
In this work we have determined that human VRK1 is
necessary for cell proliferation and thus play a role is some phase
of the cell cycle. The VRK1 gene is turned off immediately after
serum withdrawal, although the protein is very stable and last for
several days, and its expression is reactivated by addition of serum.
The loss of VRK1 results in a block of cell cycle progression in
G1/S. Expression of VRK1 gene is similar to that of immediate
early genes such as MYC or FOS and occurs before expression of
CCND1 (cyclin D1). VRK1 protein levels correlate with those of
the PCNA antigen and are inversely correlated with those of
inhibitors of the cell cycle, such as p27.
Results
VRK1 gene expression and protein level are
downregulated in serum-starved fibroblasts
The possibility that VRK1 protein level might be regulated by
entry and exit in cell cycle was determined using the human
normal fibroblast WS1 cell line. The cell cycle was stopped by
serum withdrawal in the culture that was confirmed by flow
cytometry analysis (Fig. 1A). These serum starved cells also
underwent a phenotypic change becoming more elongated and
with a lower intensity in endogenous VRK1 protein detectable by
immunofluorescence (Fig. 1B). This observation was confirmed in
an immunoblot, the serum withdrawal resulted in a drop in VRK1
protein level that was recovered upon serum readdition (Fig. 1C).
This regulation appeared to take place at the transcriptional level,
since the VRK1 message, determined by quantitative RT-PCR,
dropped after serum withdrawal and was recovered after read-
dition of serum (Fig 1D). These results suggested that VRK1 gene
expression is regulated by exit and entry into the cell cycle at the
transcriptional level and is regulated by serum.
The expression of VRK1 gene is regulated by serum at the
transcriptional level
It is known that the VRK1 protein is very stable, therefore it is
actively downregulated by an active proteolytic process that is
dependent on p53 [20], an inhibitor of cell cycle progression.
However the previous data suggested that VRK1 gene transcription
can be regulated by signals that affected entry or exit into the cell
cycle. Therefore it was determined by quantitative RT-PCR the
change in specific VRK1 RNA levels upon exit and re-entry in cell
cycle in response to serum at different time points. Upon serum
withdrawal the VRK1 RNA level fell completely in one day
(Figure 2A top), although the drop in protein level required several
days. The re-entry in cell cycle by serum readdition also occurred
within one day(Fig.2Abottom).Thesedata indicatesthat regulation
of VRK1 gene transcription is fast in response to the withdrawal, or
readdition, of serum to the cell culture. Although the complete
recovery of the protein level can take several days if the cells have
been previously serum-deprived for several days. However, a second
effect on VRK1 RNA stability can not be ruled out.
To confirm the effect of serum on VRK1 gene transcription, the
proximal promoter (21028 to +52) of the human VRK1 gene was
cloned in a luciferase reporter construct. This construct was used
to determine the effect of serum withdrawal, or readdition, on
gene transcription measured by luciferase activity. The withdrawal
of serum resulted in a loss of transcriptional activity, an activity
that was regained by readdition of serum to the cell culture
(Fig. 2B).
VRK1 is an early response gene in the G1 phase
The regulation of VRK1 gene transcription by serum suggests
that it might be regulated in the context of entry and exit in cell
cycle progression. To determine if VRK1 is an early response
gene, its expression after readdition of serum to starved cells was
compared with that of two well established early response genes,
such as MYC and FOS (Fig. 3A). The three genes, VRK1, FOS and
MYC messages started to accumulate at approximately the same
time, four hours after serum readdition. These data suggest that
VRK1, like MYC and FOS, is also an early response gene.
Next it was determined at what point is VRK1 activated when
entering the cell cycle in the WS1 fibroblast cell line. For this aim
the timing of the temporal accumulation of VRK1 transcripts was
correlated with the sequential expression of cyclin genes, since this
is a cell line with a rather slow growth. Cyclin C, cyclin D1, cyclin
E, cyclin A1 and cyclin B1 were consecutively expressed in the
expected and sequential corresponding order with a start of their
accumulation at 2, 6, 12, 16 and 17 hours respectively after serum
readdition to starved cells (Fig. 3B). The best characterized cyclin
D1 starts to be detected between four to six hours after serum
readdition. The accumulation of VRK1, FOS and MYC RNA
coincided, or started slightly sooner, than the time point of cyclin
D1 accumulation, but these three RNA continue to accumulate,
while those of cyclins peaked and drop sequentially in the correct
sequential order within the G1 phase of the cell cycle. These
results suggest that VRK1 is an early response gene in cell cycle
entry and is initially required for exit of G0 and in the early G1
phase.
Phosphorylation of Rb by the corresponding complexes of
cyclinD1/cdk determines the progression of the cell cycle to enter
in the G1/S transition [26]. The accumulation of phosho-Rb
becomes clearly detectable after twelve hours (Fig. 3C), a time
after VRK1 or cyclin D1 expression have already started to
accumulate in this cell line.
VRK1 protein level changes in relation to cell cycle
related proteins
Next it was determined in WS1 fibroblast how the changes
induced by serum deprivation in VRK1 protein levels behaved in
relation to the levels of other proteins that also change during cell
cycle progression. The PCNA protein, a DNA polymerase subunit
required for DNA synthesis [27], as well as phosphorylated
retinoblastoma (p-Rb) were used as markers of cell cycle activity
[26,28,29]. The level of p27 was used as an indicator of cell cycle
progression [30,31]. The WS1 cells were starved by serum
withdrawal for several days and the corresponding protein levels
were determined each day. VRK1 levels dropped in parallel to
those of phospho-Rb (p-Rb) or PCNA, which were reduced as a
consequence of stopping the cell cycle. This reduction in levels was
accompanied with the corresponding increase in the level of the
cell cycle inhibitor p27 (Fig. 4) as expected if cell cycle progression
is blocked [32,33]. The readdition of serum induced a recovery of
Rb phosphorylation, increased levels of VRK1 and PCNA, and
reduction of the p27 inhibitor (Fig. 4). The fast drop in VRK1
RNA levels (dashed blue line) is not accompanied by a similarly
fast drop in protein level, suggesting that the VRK1 protein (solid
blue line) is very stable, which indicates that its half-life is
approximately 4 days. This protein stability was confirmed by also
determining the stability of transfected human VRK1, both active
and kinase-dead in the presence of cycloheximide. The active
kinase, endogenous or transfected is very stable, with a half-life of
4 days; while the kinase-dead VRK1 is much more unstable and
has a shorter half life of a few hours (Fig. 5).
Human VRK1 in Cell Cycle
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Previous data indicated that VRK1 might be necessary for cell
cycle progression; therefore, its loss should be reflected as a loss of
progression markers of the cell cycle. To established this
possibility, it was determined if the loss of VRK1 induced by
siRNA could have an effect on cell cycle progression markers. For
this aim WS1 cells were transfected with either siControl or
siVRK1, and different proteins that sequentially change during the
cell cycle were also determined by immunoblot analysis. The loss
of VRK1 was accompanied by a reduction of cyclinD1 and of p-
Rb (Fig. 6), which indicates that these cells did not pass the
restriction point in the G1 phase of the cell cycle. This observation
is also supported by detection of a reduction in levels of cyclin A
and cyclin B1, as well as the proliferation marker PCNA, which
should have increased if these cells were able to progress towards
DNA synthesis. These changes in cell cycle markers induced by
siRNA VRK1 are consistent with the induction of an early block
in the G1 phase of the cell cycle; these results are also similar,
although mechanistically different, to those induced by serum
deprivation in this cell line, and therefore consistent with a role of
VRK1 in contributing to regulation of cell cycle progression.
Loss of VRK1 by siRNA interferes with cell proliferation
The early expression of VRK1 in cell cycle entry suggests that it
might be important for cell cycle progression. This observation is
consistent with the data that associates VRK1 expression to the
proliferation phenotype in tumor cell lines [34] and in human
head and neck squamous cell carcinomas [22]. It was already
known that in a human lung carcinoma cell line, loss of VRK1 by
siRNA resulted in reduced proliferation [19]. Therefore, it was
tested if in a cell line with a normal karyotype a similar effect was
observed. To determine if the loss of VRK1 affects cell division of
WS1 fibroblasts, these cells were transfected with siRNA control or
siRNA specific for VRK1 and the progression of the culture was
determined. The proliferation was slowed down as shown by a
reduction in cell number when they were treated with siVRK1,
but not in the control siRNA (Fig. 7A); a similar finding was
detected when the total amount of protein was determined. After
Figure 1. VRK1 levels in different growth conditions of human fibroblasts. (A). Flow cytometry profile of WS1 cell cycle in non-synchronized
(left) and serum starved cells (right). (B). Nuclear localization of VRK1 and morphology of WS1 cells in non-synchronized and starved WS1 cells.
Endogenous VRK1 protein was detected with a specific polyclonal antibody (VE1) in the cell nuclei. The size bar represents 50 mm. (C). Level of VRK1
endogenous protein determined in an immunoblot. (D). Change in VRK1 gene expression by qRT-PCR upon withdrawal or addition of serum to the
cell culture. These experiments were independently performed three times.
doi:10.1371/journal.pone.0001642.g001
Human VRK1 in Cell Cycle
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protein levels that was almost complete by day five, which was
accompanied by an almost complete reduction in cell division as
shown, both, by cell number or total mass. In the culture there
were fewer cells after five days of specific siRNA treatment
(Fig. 7B).
Figure 2. Changes in VRK1 RNA level upon serum withdrawal
or readdition to the culture. (A). Quantification of the VRK1 gene
expression in WS1 fibroblasts at different time points upon serum
withdrawal (top) and serum readdition to the cell culture (bottom)
which was previously serum-deprived for five days. These experiments
were independently performed three times. (B). Regulation of the
human proximal promoter of human VRK1 by serum. WS1 cells were
transfected with plasmid pGL2-B-VRK1(21028+52). The luciferase
activity was determined under different experimental conditions.
Control activity is that of cells in the continuous presence of serum.
The result is the mean of three experiments.
doi:10.1371/journal.pone.0001642.g002 Figure 3. Cell cycle gene expression induced by removal or
serum readdition. (A). Expression of MYC, FOS and VRK1 genes after
serum readdition to the culture. Before serum readdition cells were
maintained for forty hours in 0.1% FBS. (B). Sequential expression of five
cyclin genes after serum readdition to starved WS1 cells. (C). Timing of
Rb phosphorylation after serum readdition to the starved WS1 cell
culture detected with a specific anti p-Rb antibody. These experiments
were independently performed three times.
doi:10.1371/journal.pone.0001642.g003
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specific siVRK1 was determined on the expression of the
endogenous VRK1 message. The siVRK1 induced a reduction
in the level of VRK1 RNA that reached its maximum effect the
first day, and this low level was maintained throughout the time of
observation (Fig. 7C).
VRK1 and p63 in squamous epithelia
The p63 protein is mainly expressed in the basal layer of the
epithelium and where there is cell proliferation, and some p63
isoforms has been associated with stem cells, this protein persist in
the transit amplifying compartment [35–40]. Since VRK1 is
induced by exit of G0, its expression should increase as a
consequence of the first cell division. The expression of these two
proteins, p63 and VRK1, was determined by immunohistochem-
istry in the human squamous epithelium of the pharynx. As
expected the p63 signal strongly stains the first basal layer of cells
and its intensity gradually decreases (Fig. 8A). VRK1 is weakly
positive in the basal layer of the epithelium, although some
individual cells present a stronger staining (arrow), and then
suddenly increases reaching its highest intensity in the second layer
of cells, consistent with the entry of these cells in the amplification
compartment. Then VRK1 staining decreases till it disappears
and differentiated cells become negative (Fig. 8A). The timing of
the epithelial differentiation is in agreement with the half-life of
VRK1 and its disappearance. The two proteins were also detected
in immunofluorescence in pharynx (Fig. 8B), VRK1 overlaps with
p63, but interestingly in the basal layer, the compartment where
stem cells are located, only few cells have overlapping signal of
VRK1 and p63, reflecting the higher level of VRK1 in these cells,
and identifying a subpopulation within the basal layer of the
epithelium that represents approximately five per cent of the cells
in this compartment.
Discussion
Regulation of cell cycle progression is a complex process in
which the basic mechanism is determined by cyclins and cyclin-
Figure 4. Time course of changes in cell cycle related proteins
level after serum withdrawal and serum readdition to WS1
cells. The proteins were determined in an immunoblot with specific
antibodies for each protein, VRK1, p27, PCNA and phospho-Rb. The
level of actin was used as a loading control. At the bottom is shown the
quantification of the level of each protein. In the case of VRK1 it is also
shown the quantification by RT-PCR of its RNA (dashed line) at the same
time points. These experiments were independently performed three
times.
doi:10.1371/journal.pone.0001642.g004
Figure 5. Stability of endogenous or transfected VRK1 protein.
(A) The variation in levels of endogenous VRK1 and p53 proteins in
HeLa cells was followed at different time points after addition of
cycloheximide. The p53 protein drops in less than 30 minutes as
expected, but there is no detectable change in VRK1 protein even after
twelve hours suggesting it has a very high stability. (B). HEK293T cells
were transfected with plasmids expressing wild-type human VRK1 or its
kinase-dead K179E mutant. The stability of both proteins was followed
at different time points after cycloheximide addition. Cells were
transfected with plasmids pCEFL-HA-VRK1 or pCEFL-HA-VRK1(K179E)
as previously described (Vega et al., 2004). These experiments were
independently performed three times.
doi:10.1371/journal.pone.0001642.g005
Human VRK1 in Cell Cycle
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eukaryotes [1,41]. However, in mammals, the cell is within a
complex environment and its division can be affected by interactions
with neighboring cells, both homotypic and heterotypic, the
extracellular matrix as well as by the availability of growth factors;
all of them sending signals that can control cell proliferation. This
means that in mammalian cells there must be additional proteins
implicated in cell cycle regulation that mediate its adaptation to its
environment, and thus control tissue homeostasis.
In this context we have shown that VRK1 protein is necessary
for cell division. VRK1 is likely to play different roles depending
on the stage of cell cycle progression. It has to play a role in the
exit from G0, since it is immediately expressed after readdition of
serum to starved cells, and expression is turned on and off by
serum. VRK1 thus responds as an early response gene like MYC
and FOS, two prototypical early serum-response genes. Once in
the cell cycle is likely to contribute to activation of proteins needed
for cell cycle progression, or its control, since this effect is mediated
by phosphorylation of transcription factors, some of which have
been identified, such as c-Jun, ATF2 or p53. Its requirement for
cell cycle progression is supported by two observation, VRK1 gene
expression is inhibited as a downstream target of the p16INK4A-
pRB-E2F pathway [42]; and overexpression of p16 in combina-
tion with non phosphorylated retinoblastoma also inhibit VRK1
expression, since they block cell cycle progression [22]. In cells
without retinoblastoma, that functionally mimic its phosphoryla-
tion, there is an overexpression of VRK1 [43], consistent with the
permanence of these cells in a cycling state.
But VRK1, which is a very stable protein, might have additional
roles during cell cycle, as would be expected for a regulatory
kinase. Thus in cells that are growing in a continuous way, as it
occurs in cell culture o in the transit amplifying compartment of
normal epithelium, where VRK1 levels are high and colocalize
with the Ki67 proliferation markers [22]. In this situation, cells do
not enter the G0 phase, VRK1 is necessary, since its loss will result
in stoppage of cell division, as it occurs in fibroblasts (this work) or
the HCT116 cell line [19] when they were treated with siRNA in
the presence of serum. Among these roles for VRK1, there are two
for which some evidence is already available. First VRK1 can
contribute to maintain a level, albeit low, of p53 molecules in a
readiness state so that it can respond immediately to suboptimal
DNA damage in a dividing cell, without the need for induction of
TP53 gene expression, which requires hours. This action is
mediated by the specific phosphorylation of p53 in Thr18 by
VRK1 [14,19,44,45]. In fact an autoregulatory mechanism
between these two proteins has been identified, in this process
VRK1 can not induce a permanent block of cell cycle progression
by accumulation of a stabilized p53, because p53 induces
proteolytic degradation of VRK1 [20], a mechanism that is
disrupted in lung carcinomas with TP53 mutations [21]; therefore
in tumors with mutations in p53 there is an accumulation of a
protein, VRK1, necessary for cell division, and thus might
contribute to tumor cell expansion. This mechanism should be
active before DNA replication takes place, thus it is necessary in
the G1 phase of the cell cycle. Secondly, another moment in which
VRK1 might be necessary during cell cycle progression occurs late
in the cycle, just after chromosome segregation in mitosis, since
VRK1 has been shown to regulate the Baf protein, which is
necessary for assembly of the nuclear envelope [17,18]; and it is
also required for chromatin condensation, detected as phosphor-
ylation of histone 3 [46]. In addition to these roles, it is likely that
additional roles for VRK1 are identified in the future.
Thus we have reported that VRK1 protein is necessary for exit
of the G0, and maintenance of cell cycle progression where it can
play different roles depending on the phase of the cycle, and
associated to its regulatory activity as a kinase. These roles will be
defined by the future identification of specific VRK1 phosphor-
ylation substrates in each phase of the cell cycle. The requirement
of VRK1 for cell division indicates that it might be a suitable
target for development of specific inhibitors aiming to control cell
proliferation, which might be of therapeutic use in oncology as an
alternative to current and more toxic inhibitors of cell division.
Materials and Methods
Cell lines and tissue culture
The human fibroblast WS1 cell line (CRL-1502) was obtained
from the ATCC (Manassas, VA). Cells were grown in DMEM
with 10% fetal bovine serum and supplemented with antibiotics
and glutamine.
RT-PCR
WS1 cells werewashed inice-cold PBS. Total RNA was extracted
usingthe‘‘RNeasyextractionkit’’fromQuiagen(Hilden,Germany).
RNA was analyzed and quantified using a Bioanalyzer 2100 nano-
lab chipfrom Agilent Technologies (Germany). 100 ng oftotal RNA
were used in a one-step reverse transcription real-time PCR
amplification reaction using the ‘‘Quantitec SYBR Green RT-
PCR kit’’ from Qiagen in an iCycler (BioRad, Hercules, CA). The
reaction was analyzed with iCycler software (BioRad) and PCR
products were resolved in a 1.5% agarose ethidium-bromide gel.
The following forward (F) and reverse (R) primers were used for
specific human message detection. Human c-myc (Myc-F: 59-
CCAGCAGCCTCCCGCGACGATG-39;M y c - R :5 9-GAGGG-
GTCGATGCACTCTGAGG-39), human VRK1 (VRK1-F: 59-
CCAACGAGCTGCAAAACC-39;V R K 1 - R :5 9-TGTCATGTA-
GACCAGACCCCC-39), human c-fos (Fos-F: 59-ATGATGTT-
CTCGGGCTTCAACGCAGCAG-39; Fos-R: 59-AACCAATT-
CTTACTATGGCAAGCG-39), human cyclin C (CycC-F: 59-
GCCACTGCTACGGTATATTTCAAGAGATTC-39;C y c C - R :
59-CAGAAGTAGCAGCAGCAATCAATCTTG-39), human cy-
clin D1 (CycD1-F: 59-CTTCCTCTCCAAAATGCCAG-39;
CycD1-R: 59-AGAGATGGAAGGGGGAAAGA-39), human cy-
clin E (CycE-F: 59-GCAGAAGGTCTCAGGTTATC-39;C y c E - R :
59-GTGGCCTCCTTAACTTCAAG-39), human cyclin A1 (CycA-
Figure 6. Effect of siVRK1 on proteins related with cell cycle
progression. Levels of proteins in non-transfected, transfected with
siRNA control, or with siRNA specific for VRK1 were determined in after
120 hours post transfection. The proteins were determined with the
corresponding antibody indicated in the methods section, and
identified in the corresponding immunoblot. These experiments were
independently performed five times.
doi:10.1371/journal.pone.0001642.g006
Human VRK1 in Cell Cycle
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CTGTGTTGAAATCCAGCAGGAA-39), human cyclin B1
(CycB1-F: 59-TCCATTATTGATCGGTTCATGC-39;C y c B 1 - R :
59-TCAGTCACAAAAGCAAAGTCACC-39), and GAPDH am-
plification was used as internal control (GAPDH-F: 59-GGTCTTA-
CTCCTTGGAGGCCATGT-39;G A P D H - R :5 9-ACCTAACTA-
CATGGTTTACATGTT-39).
Antibodies and immunoblot analysis
For determination of protein levels, cell extracts were prepared
by homogenization in lysis buffer (Tris-HCl 50 mM pH 8,
200 mM NaCl, 5 mM EDTA, 1%Triton X-100 and protease
and phosphatase inhibitors), and 40 micrograms were loaded for
each sample in a 10% PAGE. Proteins were transferred to an
Immobilon-P membrane (Millipore), blocked in TBS-T buffer
with 5% non-fat milk, and then treated with the indicated first
specific antibody for one hour, after which after the membrane
was rinsed for 5 times, 5 minutes each time, and treated with the
corresponding secondary antibody. The signals were detected
using a chemiluminescence ECL kit (GE Healthcare). The signals
were quantified in the linear response range using an FX Personal
Imager (BioRad, Hercules, CA).
Figure 7. Effect of siRNA on endogenous VRK1 and cell proliferation. (A). Proliferation of WS1 cells that were transfected with siRNA control
or siRNA specific for VRK1. The total cell number in the dish was determined at different time points (top). The endogenous protein was detected in
an immunoblot (bottom) (B) Photograph of the WS1 cell cultures treated with siRNA control (top) or siVRK1 (bottom). The proliferation is much
slower in cells transfected with the specific siVRK1. These experiments were independently performed three times. (C). Effect on VRK1 RNA levels in
WS1 cells transfected with either siControl or siVRK1. NTC: non transfected cells.
doi:10.1371/journal.pone.0001642.g007
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polyclonal antibody, or the 1F6 murine monoclonal antibody
[47]. P27 was detected with polyclonal antibody C-19; cyclin A
with polyclonal antibody H-432; cyclin B1 with polyclonal
antibody H-433; cyclin D1 with polyclonal M-20, and PCNA
with monoclonal antibody PC10, all from Santa Cruz. Phosphor-
ylated Rb was detected with polyclonal anti-pRb (Ser807/811)
from Cell Signaling. All the antibodies were used at a 1:1000
dilution. b-actin was detected with monoclonal (Clone AC-15)
from SIGMA (St. Louis, MO) at a 1:5000 dilution. Human p63
was detected with monoclonal antibody 4A4 from Dako (Glostrup,
Denmark).
Immunofluorescence and confocal microscopy
WS1 cells were plated on 10-cm2 dishes (5610
5) containing 1-
cm-diameter sterile glass coverslips; after the corresponding serum
treatment the slides were transferred to a tissue culture test plate.
The cells were washed three times with PBS and then fixed in 4%
paraformaldehyde in PBS for 30 min at room temperature. After
fixation the cells were permeabilized in cold PBS containing 0.2%
Triton X-100 for 30 min and then treated with glycine 10 mM for
10 min at room temperature. The cells were blocked with a
solution containing 1% bovine serum albumin in PBS, at room
temperature for 30 min, and then incubated for 30 min at 37uCo r
1 h at room temperature with a mix of anti-VRK1 (VE1) in
blocking solution. The cells were washed three times with PBS
0.1% Triton X-100 and incubated with a goat anti-rabbit Cy2
labeled antibody (Amersham Biosciences) in blocking solution.
The cells were washed three times with PBS 0.1%, Triton X-100
and stained with DAPI (49,6 9-diamidino-2-phenylindol) (Sigma)
1:1000 in PBS for 10 min at room temperature. The cells were
washed with PBS, and slides were mounted with Gelvatol
(Monsanto). Subcellular localization was analyzed with a Zeiss
LSM 510 confocal microscope.
Cloning of human VRK1 gene promoter
The human VRK1 gene promoter was cloned by PCR
amplification using genomic DNA from a BAC containing this gene
(RP11-187K17 BAC library). The proximal promoter selected for
amplification comprised from position 21028 to +52. The primers
used for amplification were: Forward: 59-CCGGTACCT-
GAGGTCCTGAAGCTTACGC-39 with a KpnI site; and reverse:
59-TAGGATCCGCCGACTCGTAACTCGGCAG-39.wirh a
BamHI site. The amplified DNA was subcloned into the KpnI-BglII
restriction sites of vector pGL2-Luc (Promega). The plasmid
generated in called pGL2-B-VRK1(21028+52).The sequence of
the cloned promoter was confirmed by DNA sequencing.
Luciferase assay
WS1 cells were grown in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal calf serum and antibiotics
in 5% CO2 humidified atmosphere. For treat cells, three hours
before transfection, the medium was changed to a 0.1% FBS
DMEM. Cells were transfected with 0.5 mg of the pGL2-B-
VRK1(21028+52) and 0.5 mgo faRenilla luciferase vector (pRL-
tk). After 36 hours cells were harvested or replaced with 10% FBS
fresh medium and kept for another 24 hours. Luciferase assays
were performed with the dual reporter luciferase assay kit
(Promega). The experiment was performed three times, and each
individual measurement was determined in triplicate assays.
RNA interference experiments
Synthetic SMARTselected siRNA duplexes were purchased from
Dharmacon RNA Technologies (Lafayette, CO). The targeted
sequence for VRK1 (Accession number NM_003384) was CAAG-
GAACCTGGTGTTGAA (duplex siVRK1-2) from Dharmacon.
Functional siCONTROL non-targeting siRNA pool from Dharma-
con was used as a negative control and fluorescently labeled siGLO
Lamin A/C siRNA for silencing and transfection efficiency.
Figure 8. Localization of VRK1 and p63 in the squamous epithelium of the human pharynx. (A). Immunohistochemistry detection of p63
and VRK1 proteins in the pharynx. The arrows indicate cells (3 out of 56) in the basal layer with higher levels of VRK1. The p63 was detected with a
monoclonal antibody. VRK1 was detected with the VC1 polyclonal antibody. (B). Immunofluorescence of p63 and VRK1 in the human pharynx
epithelium. The arrows indicate cells (3 out of 57) in the basal layer that have higher levels of VRK1.
doi:10.1371/journal.pone.0001642.g008
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were carried out using Lipofectamine 2000 reagent (Invitrogen) in
WS1 cells following manufacturer instructions. After transfection,
cells were processed for western blot, immunofluorescence or video
microscopy as indicated. Viable cells were identified and counted by
exclusion of Trypan Blue staining. Also, the total amount of protein
as a function of cell number was determined.
Flow cytometry
Fibroblasts were washed three times in PBS and detached with
25% Trypsin-EDTA (Life Technologies-Gibco); detached cells
were rinsed three times with PBS by centrifugation at 1500 rpm
for 5 min in a bench centrifuge. The cell pellet was resuspended in
700 ml of 70% ethanol (precooled at 220uC) and kept at 4uC
overnight. The cells were collected by centrifugation and
resuspended in 500 ml of PBS with10 ml propidium iodide (stock
at 1 mg/ml) and 5 ml of RNAase (stock at 50 mg/ml). The cell
suspension was incubated for 1 hour at room temperature, after
which it was pass by the flow cytometer. A minimum of 10,000
cells were used for analysis. Data acquisition was performed with
the Cell Quest program (Becton-Dickinson) and analyzed with
programs Paint-a-Gate and ModFit for the cell cycle profile
(Becton-Dickinson).
Immunohistochemistry and immunofluorescence in
tissue sections
Biopsies from normal human tissues obtained with informed
consent were fixed in formalin and embedded in paraffin. Sections
(3 mm thick) were cut and transferred to positively (silanized)
charged-surface glass slides. Sections were dried for 16 hours at
56uC followed by dewaxing and rehydration through a graded
ethanol series and washed with PBS. To retrieve antigens the slides
were treated in a pressure cooker for 2 minutes in 10 mM citrate
buffer (pH6.5). Briefly, after incubation, immunodetection was
performed with the DAKO EnVision Visualization Method
(DAKO), with diaminobenzidine chromogen as the substrate
[21]. Sections were counterstained with haematoxylin. VRK1 was
detected with the VC1 polyclonal antibody [47] and p63 with
monoclonal 4A4 (DAKO).
For immunofluorescence the tissue sections, after antigen
retrieval, were blocked with 2% defatted-milk, and 0.1% Triton
in PBS, followed by washing in PBS. The slides were sequentially
stained with the antibodies, and between them they were washed
with PBS. Slide were first stained with an anti-p63 murine
monoclonal antibody for 1 hour, followed by a-mouse-FITC (1/
400) for 40 minutes at room temperature, 409 RT, next the VC1
(policlonal rabbit) (1/500) for 1 hour, and finally a-rabbit-Cy3 (1/
200) (GE Healthcare) for 40 minutes. After staining the slides were
incubated in the presence of DAPI to detect the nuclei. Cells were
mounted with Vectashield (Vector Laboratories, Burlingame, CA)
and used for examination in a Zeiss LSM510 confocal microscope.
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